New research from the University of Pittsburgh School of Medicine and La Jolla Institute for Immunology, published today in Nature Microbiology, reveals an opportunity for developing a therapy against ...

[Stay on top of transportation news: Get TTNews in your inbox.] The relationship between English proficiency and safety is a topic that has not been widely researched. However, the John A. Volpe ...

When John Spytek introduced his wife and two young sons at his Las Vegas Raiders introductory news conference last month, the team’s new general manager called his wife, Kristen, his “rock.” “You’re ...

Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...

Alzheimer's disease is the most common form of dementia, affecting more than three million Americans per year. And while its exact cause is unknown, researchers may have just had a breakthrough. A ...

Investing.com -- Leerink analyst warned that Moderna (NASDAQ:MRNA) shares could fall more than 30% if interim results from its Phase 3 CMV vaccine trial, CMVictory gives negative readout. In case of a ...

On April 16th, the U.S. Navy received its first CMV-22B at Naval Air Station (NAS) Norfolk. This aircraft, joining the fleet under the Fleet Logistics Multi-Mission Squadron (VRM) 40, nicknamed ...

The CMV-22B will provide the fleet’s medium-lift and long-range aerial logistics capability, eventually replacing the C-2A Greyhounds of Fleet Logistics Support Squadron (VRC) 40. The first CMV-22B ...

Cytomegalovirus, or CMV, is a common infection in both adults and children. Clinical trials for several vaccines are currently underway to help prevent people from developing CMV. The Centers for ...

This move will solidify its foothold in the global finance and forex trade arena CMV Capitals new office at Aspin Commercial Tower is being inaugurated by Noufal Arakkal Peeyeri, Chairman & Managing ...

At least partial data on 2-year outcomes were available for 360 children (90%). Death or CMV infection with severe disability occurred in 20 of the 149 children (13.4%) in the hyperimmune-globulin ...